Research Set to Expand as Federal Government Considers Rescheduling Cannabis from Schedule I to Schedule III with Phil Johnston Johnston Associates TRANSCRIPT
Release Date: 05/13/2024
AI Platform Facilitating Improved Accessibility to Clinical Trials with Vanessa Lemarié myTomorrows TRANSCRIPT
Empowered Patient Podcast
Vanessa Lemarié, Chief Operations Officer at myTomorrows, which is a platform for connecting patients, physicians, and clinical trial sponsors using a Trial Search AI tool designed to improve the accuracy of matching patients with suitable trials. The technology aims to speed up trial recruitment, increase diversity by reaching underserved populations, and ultimately shorten the drug development timeline. There is a particular focus on patients with no treatment options or who have not responded to current therapies. Vanessa explains, "We are all about patients. First and foremost, we want...
info_outline
AI Platform Facilitating Improved Accessibility to Clinical Trials with Vanessa Lemarié myTomorrows
Empowered Patient Podcast
Vanessa Lemarié, Chief Operations Officer at myTomorrows, which is a platform for connecting patients, physicians, and clinical trial sponsors using a Trial Search AI tool designed to improve the accuracy of matching patients with suitable trials. The technology aims to speed up trial recruitment, increase diversity by reaching underserved populations, and ultimately shorten the drug development timeline. There is a particular focus on patients with no treatment options or who have not responded to current therapies. Vanessa explains, "We are all about patients. First and foremost, we want...
info_outline
Providing Access to Uncovered Specialty Medications with Paul Pruitt SHARx TRANSCRIPT
Empowered Patient Podcast
Paul Pruitt, Chief Growth Officer at SHARx, which is a company that partners with employers to provide access to drugs not covered by insurance, such as specialty medications. The SHARx model acts as a complementary service to existing Pharmacy Benefit Managers and allows employers to opt out of covering the most expensive drugs. Paul's personal experience managing his sons' rare condition and navigating the administrative burden and frustration of the insurance system gives him deep insights into the factors driving up the cost of medications. Paul explains, "When we started SHARx eight...
info_outline
Providing Access to Uncovered Specialty Medications with Paul Pruitt SHARx
Empowered Patient Podcast
Paul Pruitt, Chief Growth Officer at SHARx, which is a company that partners with employers to provide access to drugs not covered by insurance, such as specialty medications. The SHARx model acts as a complementary service to existing Pharmacy Benefit Managers and allows employers to opt out of covering the most expensive drugs. Paul's personal experience managing his sons' rare condition and navigating the administrative burden and frustration of the insurance system gives him deep insights into the factors driving up the cost of medications. Paul explains, "When we started SHARx eight...
info_outline
AI-Powered Diagnostics and Targeted Radiotherapy for CNS Cancers with Dr. Marc Hedrick Plus Therapeutics TRANSCRIPT
Empowered Patient Podcast
Dr. Marc Hedrick, President and CEO of Plus Therapeutics Inc., has expanded their focus from glioblastoma to leptomeningeal metastasis, a central nervous system cancer that is a growing challenge due to increased survival rates from primary cancers. Their highly sensitive, advanced diagnostic test, CNSide, can detect cancer cells in cerebrospinal fluid, addressing the shortcomings of imaging and outdated standard-of-care practices. Using AI and advanced data analytics, their lead drug candidate is uniquely suited for treating CNS cancers because its safety at high doses enables the...
info_outline
AI-Powered Diagnostics and Targeted Radiotherapy for CNS Cancers with Dr. Marc Hedrick Plus Therapeutics
Empowered Patient Podcast
Dr. Marc Hedrick, President and CEO of Plus Therapeutics Inc., has expanded their focus from glioblastoma to leptomeningeal metastasis, a central nervous system cancer that is a growing challenge due to increased survival rates from primary cancers. Their highly sensitive, advanced diagnostic test, CNSide, can detect cancer cells in cerebrospinal fluid, addressing the shortcomings of imaging and outdated standard-of-care practices. Using AI and advanced data analytics, their lead drug candidate is uniquely suited for treating CNS cancers because its safety at high doses enables the...
info_outline
Proactive Care and Digital Tools Are Transforming Senior Living Facilities with Kristy Yoskey PointClickCare TRANSCRIPT
Empowered Patient Podcast
Kristy Yoskey, VP and Market Leader at PointClickCare, sees the evolution of demands of those living in senior living facilities from expecting basic housing to a desire for lifestyle choices, health services, and engagement in meaningful activities. On the facilities side, there is a shift from reactive to proactive care, where technology is used to monitor residents, identify behavioral changes, support clinical decision-making, and intervene early to prevent adverse events. In addition, the complexity of resident care is increasing, blurring the line between hospitality and healthcare and...
info_outline
Proactive Care and Digital Tools Are Transforming Senior Living Facilities with Kristy Yoskey PointClickCare
Empowered Patient Podcast
Kristy Yoskey, VP and Market Leader at PointClickCare, sees the evolution of demands of those living in senior living facilities from expecting basic housing to a desire for lifestyle choices, health services, and engagement in meaningful activities. On the facilities side, there is a shift from reactive to proactive care, where technology is used to monitor residents, identify behavioral changes, support clinical decision-making, and intervene early to prevent adverse events. In addition, the complexity of resident care is increasing, blurring the line between hospitality and healthcare and...
info_outline
Using Behavioral Science to Expand Clinical Trial Participation and Patient Engagement with Sarah Smith Oracle Life Sciences TRANSCRIPT
Empowered Patient Podcast
Sarah Smith, Qualitative Specialist and Global Behavioral Science Strategy Lead at Oracle Life Sciences, is focused on the critical role of behavioral science in improving recruitment and retention in clinical trials. Oracle Life Sciences is working to address historical underrepresentation in clinical trials by combining behavioral insights with integrated technologies to identify at-risk populations and understand barriers to participation. Using nudges to encourage trial participation, conducting decentralized trials, and applying AI to reshape patient engagement are strong tools for...
info_outline
Using Behavioral Science to Expand Clinical Trial Participation and Patient Engagement with Sarah Smith Oracle Life Sciences
Empowered Patient Podcast
Sarah Smith, Qualitative Specialist and Global Behavioral Science Strategy Lead at Oracle Life Sciences, is focused on the critical role of behavioral science in improving recruitment and retention in clinical trials. Oracle Life Sciences is working to address historical underrepresentation in clinical trials by combining behavioral insights with integrated technologies to identify at-risk populations and understand barriers to participation. Using nudges to encourage trial participation, conducting decentralized trials, and applying AI to reshape patient engagement are strong tools for...
info_outlinePhil Johnston, President and CEO of Johnston Associates, and an advisor to EO Care, the market leader in providing clinically-guided cannabis use. Phil discusses the potential for research from the reclassification of cannabis from a Schedule I drug to a Schedule III drug. With current Federal restrictions on cannabis, research has not been conducted on the potential therapeutic use for pain relief, depression, PTSD, and other conditions. With a change in classification, researchers can develop protocols, test different cannabis strains, run clinical trials, and determine dosage and form for therapies.
Phil explains, "So changing the Schedule from I to III is a game-changer because it's going to allow for research in the cannabis area in terms of dosage, what's the appropriate dosage, what kind of marijuana should be used for whatever ails you. There's a particular emphasis, of course, on pain relief and sleeplessness and depression. It appears that cannabis can have a very serious positive impact on those maladies, but we need much more research, and that's where we come in. That's what we're trying to focus on with EO Care."
"If you talk to any MD in the country, they'll tell you that they didn't learn anything about cannabis in medical school, and that was because of the Federal ban. And so there hasn't been a lot of research done. It's anecdotal at this point, such as my wife's situation, and what we need is for the Federal Government and the states to lead the way to make sure that there's funding for research and that medical schools are including that in their curricula. The research will involve what normally is involved with drugs, which is trials to determine exactly what the best treatments would be."
"Dosing is very important to figure out how much of it one needs, given whatever the specific problem is. And none of that research has been done in this country yet. Now, we're doing a sweep of international studies. It turns out that Canada, which legalized this a long time ago, has done trials and has some research, which we can adapt. However, that work has to be done, and it has to be done within medical institutions in the United States as well."
#MedicalCannabisAccessibility #MedicalCannabisClinicalResearch #MedicalCannabisCancerPatients #CannabisRescheduling #FutureofMedicalCannabis
